Aktienanalyse zu Entera Bio Ltd (ENTX)ENTXEntera Bio Ltd

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Entera Bio Ltd (ENTX) appears to be a good buy right now, trading at $2.68 with a significant upside potential. Analysts have set a price target of $11, indicating a potential upside of 310% from the current price. The company recently secured $275 million in financing, which will fully fund its Phase 3 trial for EB613, a promising osteoporosis treatment. However, the main risk is the company's net loss of $7.31 million in Q2, which reflects ongoing financial strain during its clinical development phase.

1 analysts cover ENTX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.